Citations

Showing 10 of 108152 citations.

Endorsement of reporting guidelines and study registration by endocrine and internal medicine journals: meta-epidemiological study
Zuñiga-Hernández, Jorge A , Dorsey-Treviño, Edgar Gerardo , González‐González, José Gerardo , Brito, Juan P. , Rodríguez‐Gutiérrez, René , Zuñiga-Hernandez, Jorge Alberto , Rodríguez-Gutiérrez, René , González-González, José Gerardo , Brito, Juan P , Montori, Víctor M.

Mayo Clinic

BMJ Open | September 26, 2019 | Volume: 9 | Issue: 9 | Pages: e031259

10.1136/bmjopen-2019-031259 | PMID 31558457 Get It

Objectives To improve the trustworthiness of evidence, studies should be prospectively registered and research reports should adhere to existing standards. We aimed to systematically assess the degree to which endocrinology and internal medicine journals endorse study registration and reporting standards for randomised controlled trials (RCTs), systematic reviews (SRs) and observational studies (ObS). Additionally, we evaluated characteristics that predict endorsement of reporting or registration mechanism by these journals. Design Meta-epidemiological study. Setting Journals included in the ‘Endocrinology and Metabolism’ and ‘General and Internal Medicine’ 2017 Journal Citation Reports. Participants Journals with an impact factor of ≥1.0, focused on clinical medicine, and those who publish RCTs, SRs and ObS were included. Primary outcomes Requirement of adherence to reporting guideline and study registration as determined from the journals’ author instructions. Results Of the 170 (82 endocrinology and 88 internal medicine) eligible journals, endorsing of reporting standards was the highest for RCTs, with 35 (43%) of endocrine journals and 55 (63%) of internal medicine journals followed by SRs, with 21 (26%) and 48 (55%), respectively, and lastly, by ObS with 41 (50%) of endocrine journals and 21 (24%) of internal medicine journals. In 78 (46%) journals RCTs were required to be registered and published in adherence to the Consolidated Standards of Reporting Trials statement. Only 11 (6%) journals required registration of SRs. Internal medicine journals were more likely to endorse reporting guidelines than endocrine journals except for Strengthening the Reporting of Observational Studies in Epidemiology. No other journal characteristic proved to be an independent predictor of reporting standard endorsement for RCTs besides trial registration. Conclusion Our results highlight that study registration requirement and reporting guideline endorsement are suboptimal in internal medicine and endocrine journals. This malpractice may be further enhanced since endorsement does not imply enforcement, impairing the practice of evidence-based medicine.
Top Ten Tips Palliative Care Clinicians Should Know About Physical Medicine and Rehabilitation
Brassil, Michelle E., Zheng, Jasmine , Smith, Sean R. , Tolchin, Dorothy W. , Wittry, Sarah A. , Jones, Christopher A. , Chernack, Betty, Cheville, Andrea , Jones, C. P.

Mayo Clinic

Journal of Palliative Medicine | September 26, 2019 | Volume: 23 | Issue: 1 | Pages: 129-135

10.1089/jpm.2019.0440 | PMID 31556786 Get It

Physical medicine and rehabilitation (PM&R) is a specialty of medicine focused on optimizing function and quality of life for individuals with physical impairments, injuries, or disabling illnesses. Given the sometimes acute nature of the loss of function and even loss of independence, there are significant palliative care (PC) needs within patients seen by PM&R. This article, written by a team of PM&R and PC specialists, aims to help the PC team better understand the world of postacute care, expand their toolkit for treating musculoskeletal and neurological symptoms, improve prognostication for patients with brain and spinal cord injuries, and decide when patients may benefit from PM&R consultation and support. There is significant overlap between the populations treated by PM&R and PC. Better integration between these specialties will help patients to maintain independence as well as advance excellent patient-centered care.
Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry
Xian, Ying , Li, Zhuokai , Robinson, Jennifer G. , Louie, Michael J. , Koren, Andrew , Goldberg, Anne C. , Roger, Véronique L. , Wilson, Peter W.F. , Wang, Tracy Y., Návar, Ann Marie , Li, Shuang, Virani, Salim S. , Peterson, Eric D.

Mayo Clinic

Journal of the American Heart Association | September 26, 2019 | Volume: 8 | Issue: 19 | Pages: No page available

10.1161/jaha.119.013229 | PMID 31554462 Get It

Background Current treatment guidelines strongly recommend statin therapy for secondary prevention. However, it remains unclear whether patients’ perceptions of cardiovascular risk, beliefs on cholesterol, or the intensity of prescribed statin therapy differs for patients with coronary artery disease ( CAD ) versus cerebrovascular disease (Ce VD ) versus both CAD and Ce VD ( CAD &Ce VD ). Methods and Results The PALM (Patient and Provider Assessment of Lipid Management) registry collected data on statin use, intensity, and core laboratory low‐density lipoprotein cholesterol levels for 3232 secondary prevention patients treated at 133 US clinics. Among individuals with Ce VD only (n=403), CAD only (n=2202), and Ce VD & CAD (n=627), no significant differences were observed in patient‐perceived cardiovascular disease risk, beliefs on cholesterol lowering, or perceived effectiveness and safety of statin therapy. However, patients with Ce VD only were less likely to receive any statin therapy (76.2% versus 86.2%; adjusted odds ratio 0.64, 95% CI 0.45–0.91), or guideline‐recommended statin intensity (34.6% versus 50.4%; adjusted odds ratio 0.60, 95% CI 0.45–0.81) than those with CAD only. Individuals with Ce VD only were also less likely to achieve low‐density lipoprotein cholesterol <100 mg/ dL (59.2% versus 69.7%; adjusted odds ratio 0.79, 95% CI 0.64–0.99) than individuals with CAD alone. There were no significant differences in the use of any statin therapy or guideline‐recommended statin intensity between individuals with CAD &Ce VD and those with CAD only. Conclusions Despite lack of significant differences in patient‐perceived cardiovascular risk or statin beliefs, patients with Ce VD were significantly less likely to receive higher intensity statin or achieve low‐density lipoprotein cholesterol <100 mg/ dL than those with CAD only.
Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)
Luke, Jason J. , Olson, Daniel J. , Allred, Jacob B., Bao, Riyue , Zha, Yuanyuan , Labadie, Brian , Bastos, Bruno R. , Butler, Marcus O. , Hogg, David , Strand, Carrie A, Zha, Yuanyuan , Butler, Marcus O , Luke, Jason J , Strand, Carrie , Carll, Timothy Clifford , Münster, Pamela N. , Schwartz, Gary K.

Mayo Clinic

Clinical Cancer Research | September 26, 2019 | Volume: 26 | Issue: 4 | Pages: 804-811

10.1158/1078-0432.ccr-19-1223 | PMID 31558480 Get It

Abstract Purpose: The surface receptor MET is highly expressed on primary uveal melanoma; MET inhibitors demonstrated early clinical signals of efficacy in slowing uveal melanoma growth. The primary objective of our study was to compare the progression-free survival rate at 4 months (PFS4) of patients with uveal melanoma treated with cabozantinib or chemotherapy. Patients and Methods: Patients with metastatic uveal melanoma and RECIST measurable disease were randomized 2:1 to receive either cabozantinib (arm 1) versus temozolomide or dacarbazine (arm 2) with restaging imaging every two cycles. Cross-over from arm 2 to cabozantinib after progression was allowed (arm 2X). Available tumor specimens were analyzed by whole-exome sequencing (WES) and results were correlated with outcome. Results: Forty-six eligible patients were accrued with 31, 15, and 9 in arms 1, 2, and 2X, respectively. Median lines of prior therapy, including hepatic embolization, were two. Rates of PFS4 in arm 1 and arm 2 were 32.3% and 26.7% (P = 0.35), respectively, with median PFS time of 60 and 59 days (P = 0.964; HR = 0.99). Median overall survival (OS) was 6.4 months and 7.3 months (P = 0.580; HR = 1.21), respectively. Grade 3–4 Common Terminology Criteria for Adverse Events were present in 61.3%, 46.7%, and 37.5% in arms 1, 2, and 2X, respectively. WES demonstrated a mean tumor mutational burden of 1.53 mutations/Mb and did not separate OS ≤ or &gt;1 year (P = 0.14). Known mutations were identified by WES and novel mutations were nominated. Conclusions: MET/VEGFR blockade with cabozantinib demonstrated no improvement in PFS but an increase in toxicity relative to temozolomide/dacarbazine in metastatic uveal melanoma.
A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition
Shee, Kevin , Wells, Jason D. , Ung, Matthew , Hampsch, Riley A. , Traphagen, Nicole A. , Liu, Stephanie C., Zeldenrust, Megan A., Wang, Liewei , Yu, Jia , Demidenko, Eugene , Kettenbach, Arminja N. , Miller, Todd W. , Cheng, Chao , Yang, Wei , Kalari, Krishna R. , Boughey, Judy C. , Cheng, Chao , Goetz, Matthew P.

Mayo Clinic

Clinical Cancer Research | September 26, 2019 | Volume: 26 | Issue: 1 | Pages: 159-170

10.1158/1078-0432.ccr-18-2213 | PMID 31558472 Get It

Abstract Purpose: We hypothesized that integrated analysis of cancer types from different lineages would reveal novel molecularly defined subgroups with unique therapeutic vulnerabilities. On the basis of the molecular similarities between subgroups of breast and ovarian cancers, we analyzed these cancers as a single cohort to test our hypothesis. Experimental Design: Identification of transcriptional subgroups of cancers and drug sensitivity analyses were performed using mined data. Cell line sensitivity to Hsp90 inhibitors (Hsp90i) was tested in vitro. The ability of a transcriptional signature to predict Hsp90i sensitivity was validated using cell lines, and cell line- and patient-derived xenograft (PDX) models. Mechanisms of Hsp90i sensitivity were uncovered using immunoblot and RNAi. Results: Transcriptomic analyses of breast and ovarian cancer cell lines uncovered two mixed subgroups comprised primarily of triple-negative breast and multiple ovarian cancer subtypes. Drug sensitivity analyses revealed that cells of one mixed subgroup are significantly more sensitive to Hsp90i compared with cells from all other cancer lineages evaluated. A gene expression classifier was generated that predicted Hsp90i sensitivity in vitro, and in cell line- and PDXs. Cells from the Hsp90i-sensitive subgroup underwent apoptosis mediated by Hsp90i-induced upregulation of the proapoptotic proteins Bim and PUMA. Conclusions: Our findings identify Hsp90i as a potential therapeutic strategy for a transcriptionally defined subgroup of ovarian and breast cancers. This study demonstrates that gene expression profiles may be useful to identify therapeutic vulnerabilities in tumor types with limited targetable genetic alterations, and to identify molecularly definable cancer subgroups that transcend lineage.
Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?
Novo, Mattia , Nowakowski, Grzegorz S. , Micallef, Ivana N. , Johnston, Patrick B. , Inwards, David J. , Botto, Barbara , Ristow, Kay M., Vitolo, Umberto , Ansell, Stephen M. , Vitolo, Umberto , Habermann, Thomas M. , Witzig, Thomas E. , Young, Jason R.

Mayo Clinic

Leukemia & Lymphoma | September 26, 2019 | Volume: 61 | Issue: 2 | Pages: 318-327

10.1080/10428194.2019.1663422 | PMID 31556355 Get It

Mucocele of the appendix presenting as an exacerbated chronic tubo-ovarian abscess
Čubro, Hajrunisa, Cengić, Vesna, Burina, Nina, Kravic, Zlatko, Beciragic, Esad, Vranić, Semir

Mayo Clinic

Medicine | September 26, 2019 | Volume: 98 | Issue: 39 | Pages: e17149

10.1097/md.0000000000017149 | PMID 31574819 Get It

Abstract Rationale: Appendiceal mucocele is a rare entity of mucinous cystic dilatation of the appendix. It has no typical clinical presentation and is considered a potentially premalignant condition. Patient concerns: We present a case of accidental intraoperative finding of an appendiceal mucocele in a 54-year old woman that clinically presented with an exacerbated chronic tubo-ovarian abscess. Diagnoses: Trans-vaginal ultrasonography showed an encapsulated, oval, unilocular mass above the uterus with a heteroechogenic structure, homogeneous fluid content, and smooth regular walls without inner proliferation. The histopathologic diagnosis was consistent with an appendiceal cystadenoma. Interventions: The patient underwent a simple appendectomy. Outcomes: There were no clinical, biochemical or imaging signs of the disease recurrence at 6 months follow up. Lessons: To our knowledge, this is the only well-documented case of appendiceal mucocele mimicking exacerbated chronic tubo-ovarian abscess reported in the literature. Awareness of a rare entity such as an appendiceal mucocele, which is frequently misdiagnosed as a potential cause of acute abdomen, is necessary for the appropriate management strategy in order to prevent complications.
Cost of Readmissions Following Anterior Cervical Discectomy and Fusion: Insights from the Nationwide Readmissions Database
Bhandarkar, Archis R. , Alvi, Mohammed Ali , Kerezoudis, Panagiotis , Yolcu, Yagiz U. , Habermann, Elizabeth B. , Sebastian, Arjun S. , Bydon, Mohamad , Habermann, Elizabeth , Alvi, Mohammed Ali , Goyal, Anshit

Mayo Clinic

Neurosurgery | September 26, 2019 | Volume: 87 | Issue: 4 | Pages: 679-688

10.1093/neuros/nyz443 | PMID 31642499 Get It

Abstract BACKGROUND Postoperative readmissions are a significant driver of variation in bundled care costs associated with cervical spine surgery. OBJECTIVE To determine the factors predicting the cost of readmission episodes following elective anterior cervical discectomy and fusion (ACDF). METHODS We queried the Healthcare Cost and Utilization Project Nationwide Readmissions Database for patients undergoing elective ACDF during 2012 to 2015. Multivariable linear regression was performed to establish the factors associated with the cost of each 30-/90-d readmission episode. RESULTS A total of 139 877 and 113 418 patients met inclusion criteria for the evaluation of 30- and 90-d readmissions, respectively. Among these, the national rates of 30- and 90-d readmission after an elective ACDF were 3% and 6%, respectively. The median cost of a 30- and 90-d readmission episode was $6727 (IQR: $3844-$13 529) and $8507 (IQR: $4567-$17 460), respectively. Relative predictor importance analysis revealed that the number of procedures at index admission (IA), length of stay at IA, and time elapsed between index surgical admission and readmission were the top predictors of both 30- and 90-d readmission costs (all P < .001). Although cervical myelopathy accounted for only 3.6% of all 30-d readmissions, it accounted for the largest share (8%) of 30-d readmission costs. CONCLUSION In this analysis from a national all-payer database, we determined the factors associated with the cost of readmissions following elective ACDF. These results are important in assisting policymakers and payers with a better risk adjustment in bundled care payment systems and for surgeons in implementing readmission cost-reduction efforts.
Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: A double‐blind placebo‐controlled trial of levothyroxine (L‐T4) and triiodothyronine (T3)
Núñez, Nicolás A. , Frye, Mark A.

Mayo Clinic

Bipolar Disorders | September 26, 2019 | Volume: 21 | Issue: 8 | Pages: 684-685

10.1111/bdi.12842 | PMID 31556192 Get It

Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg
Turner, Lindsey E., Pittock, Sean J. , McEvoy, Marian T., Pittock, S J , Flanagan, Eoin P.

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | September 26, 2019 | Volume: 6 | Issue: 6 | Pages: No page available

10.1212/nxi.0000000000000620 | PMID 31554670 Get It